ASCO Gynecologic Cancer | Conference

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.